Literature DB >> 9925547

Primary targets of fluoroquinolones in Streptococcus pneumoniae.

H Fukuda1, K Hiramatsu.   

Abstract

Mutants of wild-type Streptococcus pneumoniae IID553 with mutations in parC were obtained by selection with trovafloxacin, levofloxacin, norfloxacin, and ciprofloxacin. All of the parC mutants were cross-resistant to the selecting agents but were not resistant to gatifloxacin and sparfloxacin. On the other hand, gyrA mutants were isolated by selection with gatifloxacin and sparfloxacin. The gyrA mutants were cross-resistant to gatifloxacin and sparfloxacin but were not resistant to the other fluoroquinolones tested. These results suggest that in wild-type S. pneumoniae the primary target of trovafloxacin, levofloxacin, norfloxacin, and ciprofloxacin is topoisomerase IV, whereas the primary target of gatifloxacin and sparfloxacin is DNA gyrase.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9925547      PMCID: PMC89092     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Chemiluminescent detection of DNA: application for DNA sequencing and hybridization.

Authors:  S Beck; T O'Keeffe; J M Coull; H Köster
Journal:  Nucleic Acids Res       Date:  1989-07-11       Impact factor: 16.971

2.  ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype.

Authors:  R Muñoz; A G De La Campa
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

3.  Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.

Authors:  X S Pan; L M Fisher
Journal:  J Bacteriol       Date:  1996-07       Impact factor: 3.490

4.  Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus.

Authors:  J Yamagishi; T Kojima; Y Oyamada; K Fujimoto; H Hattori; S Nakamura; M Inoue
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

5.  Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli.

Authors:  H Yoshida; M Bogaki; M Nakamura; S Nakamura
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

6.  Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.

Authors:  E Y Ng; M Trucksis; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

7.  In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone.

Authors:  M Hosaka; T Yasue; H Fukuda; H Tomizawa; H Aoyama; K Hirai
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

8.  Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.

Authors:  L Ferrero; B Cameron; B Manse; D Lagneaux; J Crouzet; A Famechon; F Blanche
Journal:  Mol Microbiol       Date:  1994-08       Impact factor: 3.501

9.  Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli.

Authors:  H Yoshida; M Bogaki; M Nakamura; L M Yamanaka; S Nakamura
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

10.  Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus.

Authors:  L Ferrero; B Cameron; J Crouzet
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

View more
  59 in total

1.  Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.

Authors:  J M Blondeau; X Zhao; G Hansen; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

2.  Association of alterations in ParC and GyrA proteins with resistance of clinical isolates of Enterococcus faecium to nine different fluoroquinolones.

Authors:  S Brisse; A C Fluit; U Wagner; P Heisig; D Milatovic; J Verhoef; S Scheuring; K Köhrer; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

3.  In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus.

Authors:  M Boos; S Mayer; A Fischer; K Köhrer; S Scheuring; P Heisig; J Verhoef; A C Fluit; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

4.  Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.

Authors:  M Takei; H Fukuda; R Kishii; M Hosaka
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

5.  Evaluation of susceptibility testing to detect fluoroquinolone resistance mechanisms in Streptococcus pneumoniae.

Authors:  D C Richardson; D Bast; A McGeer; D E Low
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 6.  Efflux-mediated resistance to fluoroquinolones in gram-positive bacteria and the mycobacteria.

Authors:  K Poole
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

7.  Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae.

Authors:  H Fukuda; R Kishii; M Takei; M Hosaka
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

8.  Longitudinal assessment of antipneumococcal susceptibility in the United States.

Authors:  Mark E Jones; James A Karlowsky; Renée Blosser-Middleton; Ian A Critchley; Elena Karginova; Clyde Thornsberry; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

9.  Real-time PCR and high-resolution melt analysis for rapid detection of Mycobacterium leprae drug resistance mutations and strain types.

Authors:  Wei Li; Masanori Matsuoka; Masanori Kai; Pratibha Thapa; Saraswoti Khadge; Deanna A Hagge; Patrick J Brennan; Varalakshmi Vissa
Journal:  J Clin Microbiol       Date:  2011-12-14       Impact factor: 5.948

10.  Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.

Authors:  X S Pan; G Yague; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.